National Academies Press: OpenBook
« Previous: Appendix B: Disclosure of Unavoidable Conflict of Interest
Suggested Citation:"Appendix C: Open Session Agendas." National Academies of Sciences, Engineering, and Medicine. 2021. Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine. Washington, DC: The National Academies Press. doi: 10.17226/26350.
×
Page 301
Suggested Citation:"Appendix C: Open Session Agendas." National Academies of Sciences, Engineering, and Medicine. 2021. Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine. Washington, DC: The National Academies Press. doi: 10.17226/26350.
×
Page 302
Suggested Citation:"Appendix C: Open Session Agendas." National Academies of Sciences, Engineering, and Medicine. 2021. Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine. Washington, DC: The National Academies Press. doi: 10.17226/26350.
×
Page 303
Suggested Citation:"Appendix C: Open Session Agendas." National Academies of Sciences, Engineering, and Medicine. 2021. Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine. Washington, DC: The National Academies Press. doi: 10.17226/26350.
×
Page 304
Suggested Citation:"Appendix C: Open Session Agendas." National Academies of Sciences, Engineering, and Medicine. 2021. Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine. Washington, DC: The National Academies Press. doi: 10.17226/26350.
×
Page 305
Suggested Citation:"Appendix C: Open Session Agendas." National Academies of Sciences, Engineering, and Medicine. 2021. Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine. Washington, DC: The National Academies Press. doi: 10.17226/26350.
×
Page 306
Suggested Citation:"Appendix C: Open Session Agendas." National Academies of Sciences, Engineering, and Medicine. 2021. Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine. Washington, DC: The National Academies Press. doi: 10.17226/26350.
×
Page 307
Suggested Citation:"Appendix C: Open Session Agendas." National Academies of Sciences, Engineering, and Medicine. 2021. Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine. Washington, DC: The National Academies Press. doi: 10.17226/26350.
×
Page 308
Suggested Citation:"Appendix C: Open Session Agendas." National Academies of Sciences, Engineering, and Medicine. 2021. Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine. Washington, DC: The National Academies Press. doi: 10.17226/26350.
×
Page 309
Suggested Citation:"Appendix C: Open Session Agendas." National Academies of Sciences, Engineering, and Medicine. 2021. Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine. Washington, DC: The National Academies Press. doi: 10.17226/26350.
×
Page 310
Suggested Citation:"Appendix C: Open Session Agendas." National Academies of Sciences, Engineering, and Medicine. 2021. Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine. Washington, DC: The National Academies Press. doi: 10.17226/26350.
×
Page 311
Suggested Citation:"Appendix C: Open Session Agendas." National Academies of Sciences, Engineering, and Medicine. 2021. Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine. Washington, DC: The National Academies Press. doi: 10.17226/26350.
×
Page 312

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

C Open Session Agendas SEPTEMBER 22, 2020 CLOSED SESSION FULL SCHEDULE IN EASTERN TIME 11:00-11:15 Welcome Guy Palmer, Committee Chair 11:15-12:45 Bias and Conflict of Interest Discussion Lauren Shern, Director of Policy, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine 12:45-1:00 Review Statement of Task and Study Timeline Guy Palmer, Committee Chair 1:00-1:30 Framing the Report for Policy Makers Julie Eubank, Assistant Director, Congressional and Government Affairs, National Academies of Sciences, Engineering, and Medicine 1:30 Adjourn SEPTEMBER 23, 2020 OPEN SESSION FULL SCHEDULE IN EASTERN TIME 11:00-11:10 Welcome Guy Palmer, Committee Chair 11:10-11:50 Sponsor Orientation to Statement of Task Jane Knisely, Program Officer, Bacteriology and Mycology Branch, National Institute of Allergy and Infectious Diseases (NIAID) C-1 PREPUBLICATION COPY: UNCORRECTED PROOFS

C-2 COMBATING AMR AND PROTECTING THE MIRACLE OF MODERN MEDICINE 11:50-12:15 ASPE Involvement on the National Strategy for Combating Antimicrobial- Resistant Bacteria Amanda Cash, Director, Division of Evidence, Evaluation, and Data Policy, Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services 12:15-12:40 USDA Involvement on the National Strategy for Combating Antimicrobial- Resistant Bacteria Neena Anadaraman, Veterinary Science Policy Advisor, Office of the Chief Scientist, U.S. Department of Agriculture (USDA) 12:40-1:05 NIH Involvement on the National Strategy for Combating Antimicrobial- Resistant Bacteria Jane Knisely, Program Officer, Bacteriology and Mycology Branch, NIAID 1:05-1:30 BARDA Involvement on the National Strategy for Combating Antimicrobial-Resistant Bacteria Mark Albrecht, Branch Chief, Anti-Bacterial Program, Division of CBRN Countermeasures, Biomedical Advanced Research and Development Authority (BARDA) 1:30 Adjourn SEPTEMBER 24, 2020 OPEN SESSION FULL SCHEDULE IN EASTERN TIME 11:00-11:05 Welcome Guy Palmer, Committee Chair 11:05-11:30 USAID Involvement on the National Strategy for Combating Antimicrobial- Resistant Bacteria Jessica Petrillo, Senior Advisor for Antimicrobial Resistance and GHSA, Emerging Threats Division, Office of Infectious Diseases, Bureau for Global Health, U.S. Agency for International Development 11:30-11:55 FDA Involvement on the National Strategy for Combating Antimicrobial- Resistant Bacteria William Flynn, Deputy Director for Science Policy, Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA) 11:55-12:20 CDC Involvement on the National Strategy for Combating Antimicrobial- Resistant Bacteria Michael Craig, Senior Advisor for Antibiotic Resistance, Antibiotic Resistance Coordination and Strategy Unit, Centers for Disease Control and Prevention PREPUBLICATION COPY: UNCORRECTED PROOFS

APPENDIX C C-3 12:20-12:45 Department of Defense Involvement on the National Strategy for Combating Antimicrobial-Resistant Bacteria Paige Waterman, CARB Task Force Lead, Walter Reed Army Institute of Research, U.S. Department of Defense 12:45-1:30 Q&A 1:30 Adjourn SEPTEMBER 25, 2020 CLOSED SESSION FULL SCHEDULE IN EASTERN TIME 11:00-1:30 Closed session for committee deliberations. 1:30 Adjourn NOVEMBER 9, 2020 OPEN SESSION FULL SCHEDULE IN EASTERN TIME 11:00-11:05 Welcome Guy Palmer, Committee Chair 11:05-11:35 Additional Federal Actions Needed to Determine Magnitude and Reduce Impact of Antibiotic Resistance Timothy Persons, Chief Scientist and Managing Director, Science, Technology Assessment, and Analytics, U.S. Government Accountability Office Mary Denigan-Macauley, Director, Health Care, Public Health & Private Markets, U.S. Government Accountability Office 11:35-12:05 Convergence in Antimicrobial Use and Factor Influencing Resistance Ramanan Laxminarayan, Director and Senior Fellow, Center for Disease Dynamics, Economics & Policy 12:05-12:15 Break 12:15-12:45 Measuring the Impacts of FDA’s Actions to Promote Judicious Antimicrobial Use in Veterinary Medicine Susan Bright, Veterinary Medical Officer, Office of Surveillance & Compliance, Center for Veterinary Medicine, FDA 12:45-1:15 National Scale Monitoring of Antimicrobial Resistance in Surface Water Jay Garland, Senior Research Scientist, Office of Research and Development, U.S. Environmental Protection Agency PREPUBLICATION COPY: UNCORRECTED PROOFS

C-4 COMBATING AMR AND PROTECTING THE MIRACLE OF MODERN MEDICINE 1:15-1:45 International Activities in AMR, Department of Health and Human Services Lynn Filpi, AMR Team Lead, Senior Global Health Officer, Pandemic and Emerging Threat Office, Office of Global Affairs, HHS 1:45-2:00 Closing Questions 2:00 Adjourn NOVEMBER 10, 2020 OPEN SESSION FULL SCHEDULE IN EASTERN TIME 11:00-11:05 Welcome Guy Palmer, Committee Chair 11:05-11:35 Monitoring Countries’ Progress on Tripartite Global Action Plan Anand Balachandran, Unit Head, AMR National Action Plans and Monitoring & Evaluation, AMR Division, World Health Organization (WHO)–Headquarters 11:35-12:05 The Norwegian National Strategy Against Antibiotic Resistance Gunnar Skov Simonsen, Professor of Clinical Microbiology, University of Tromsø; Director of the Department of Microbiology and Infection Control, University Hospital of North Norway 12:05-12:15 Break 12:15-12:45 Antibiotic Resistance in the Food Chain Frank Møller Aarestrup, Professor, Head of Division, Division for Global Surveillance, Research Group for Genomic Epidemiology, National Food Institute, Technical University of Denmark 12:45-1:15 Antimicrobial Use in Companion Animals Mark Papich, Professor of Clinical Pharmacology, Burroughs Wellcome Fund Professorship in Veterinary Pharmacology, College of Veterinary Medicine, North Carolina State University 1:15-1:45 Antimicrobial Use in Chilean Aquaculture Felipe C. Cabello, Professor Emeritus, Department of Microbiology and Immunology, New York Medical College 1:45-2:00 Closing Questions 2:00 Adjourn NOVEMBER 11, 2020 OPEN SESSION PREPUBLICATION COPY: UNCORRECTED PROOFS

APPENDIX C C-5 FULL SCHEDULE IN EASTERN TIME 11:00-11:05 Welcome Guy Palmer, Committee Chair 11:05-11:35 The Global Antibiotic-Resistance Surveillance System Carmem L Pessoa-Silva, Unit Head - Surveillance, Evidence and Laboratory Strengthening, AMR Division, WHO 11:35-12:05 Shaping Strategies for Prevention and Response to Antibiotic Resistance Tim Jinks, Head Drug-Resistant Infections Priority Program, Wellcome Trust 12:05-12:15 Break 12:15-12:45 The Fleming Fund Support for AMR Surveillance Tom Pilcher, Head of Country Coordination, The Fleming Fund, Department of Health and Social Care Claire Gordon, Lead Clinical Microbiologist, Mott MacDonald/The Fleming Fund 12:45-1:15 The Bill & Melinda Gates Foundation’s Strategy in AMR Padmini Srikantiah, Senior Program Officer, Global Health Antimicrobial Resistance Strategy Lead, Bill & Melinda Gates Foundation 1:45-2:00 Questions and Discussion 2:00 Adjourn NOVEMBER 13, 2020 CLOSED SESSION FULL SCHEDULE IN EASTERN TIME 11:00-12:30 Debrief on Presentations Guy Palmer, Committee Chair 12:30-1:30 Next Steps Guy Palmer, Committee Chair 1:30 Adjourn PREPUBLICATION COPY: UNCORRECTED PROOFS

C-6 COMBATING AMR AND PROTECTING THE MIRACLE OF MODERN MEDICINE JANUARY 5, 2021 OPEN SESSION THE ANTIMICROBIAL PRODUCT PIPELINE AND INCENTIVES FOR MARKET VIABILITY FULL SCHEDULE IN EASTERN TIME 11:00-11:05 Welcome Guy Palmer, Committee Chair 11:05-11:30 The Post-Approval Challenges of Antimicrobial Development Kevin Krause, Vice President, Clinical Science and Development Operations, AN2 Therapeutics Inc. 11:30-11:55 Pricing of Antibiotics and Proposals to Strengthen the Pipeline John Rex, Chief Medical Officer and Director, F2G, Ltd; Editor-in-Chief, AMR Solutions; Operating Partner, Advent Life Sciences 12:00-12:15 Break 12:15-1:45 Panel Discussion on Push and Pull Incentives Lefteris Mylonakis, Moderator Wes Kim, Senior Officer, Antibiotic Resistance Project, The Pew Charitable Trusts Kevin Outterson, Executive Director, Combating Antibiotic-Bacteria Biopharmaceutical Accelerator Ryan Cirz, CSO and Acting CEO, Revagenix, Inc. Mark Albrecht, Branch Chief, Anti-Bacterial Program, Division of CBRN Countermeasures, BARDA 1:45-2:10 Championing Patient and Public Health Needs: IDSA Efforts to Strengthen the Antibiotic Pipeline Helen Boucher, Chief, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center Director, Levy Center for Integrated Management of Antimicrobial Resistance Treasurer, Infectious Diseases Society of America 2:10-2:35 A New, Sustainable Model for Antibiotic R&D Brad Spellberg, Chief Medical Officer, Los Angeles County-University of Southern California Medical Center 2:45 Adjourn PREPUBLICATION COPY: UNCORRECTED PROOFS

APPENDIX C C-7 JANUARY 6, 2021 OPEN SESSION DIAGNOSTICS AND SUSCEPTIBILITY TESTING FULL SCHEDULE IN EASTERN TIME 11:00-11:05 Welcome Guy Palmer, Committee Chair 11:05-11:30 The Relationship Between Antimicrobial Susceptibility Testing Devices and Antibiotic Markets Kevin Krause, Vice President, Clinical Science and Development Operations, AN2 Therapeutics Inc. 11:30-11:55 Regulatory Challenges in Antimicrobial Diagnostics Barbara Zimmer, Principal Scientist, Microbiology Scientific Affairs, Beckman Coulter, Inc. 11:55-1:15 Diagnostics Panel Discussion Jenn Dien Bard, Moderator Mark Miller, Chief Medical Officer, bioMerieux Fred C. Tenover, Vice President, Scientific Affairs, Cepheid Angela Caliendo, Warren Alpert Foundation Professor of Medicine, Executive Vice Chair of Medicine, Alpert Medical School, Brown University Barbara Zimmer, Principal Scientist, Microbiology Scientific Affairs, Beckman Coulter, Inc. 1:15-1:30 Break 1:30-1:50 VetCAST Susceptibility Test Breakpoints Peter Panduro Damborg, Associate Professor, Veterinary Clinical Microbiology, University of Copenhagen 1:50-2:10 Addressing Challenges in Veterinary Diagnostics Brian Lubbers, Associate Professor, College of Veterinary Medicine, Kansas State University 2:10-2:45 Discussion on Veterinary Diagnostics and Susceptibility Test Breakpoints Emmanuel Okello, Moderator Peter Panduro Damborg, Associate Professor, Veterinary Clinical Microbiology, University of Copenhagen Brian Lubbers, Associate Professor, College of Veterinary Medicine, Kansas State University 2:45 Adjourn PREPUBLICATION COPY: UNCORRECTED PROOFS

C-8 COMBATING AMR AND PROTECTING THE MIRACLE OF MODERN MEDICINE JANUARY 7, 2020 OPEN SESSION ANTIMICROBIAL STEWARDSHIP FULL SCHEDULE IN EASTERN TIME 11:00-11:05 Welcome Guy Palmer, Committee Chair 11:05-11:30 Telehealth and Antimicrobial Stewardship John Lynch, Associate Medical Director, Harborview Medical Center Antimicrobial Stewardship Program; Associate Professor, Division of Allergy and Infectious Diseases, University of Washington School of Medicine 11:30-11:55 Antimicrobial Stewardship in Remote Areas Marc Mendelson, Professor of Infectious Disease, Division of Infectious Diseases & HIV Medicine, University of Cape Town 11:55-12:20 Antimicrobial Stewardship in Nursing Homes: Barriers and Opportunities Chris Crnich, Chief of Medicine, Madison VA Hospital; Associate Professor of Medicine, Division of Infectious Diseases, University of Wisconsin School of Medicine and Public Health 12:20-12:35 Break 12:35-1:00 The Road to Research and Development of Alternatives to Antibiotics in the United States Cyril Gay, Senior National Program Leader, Animal Production and Protection, Agricultural Research Service, USDA 1:00-2:30 Panel Discussion on Incentives for Stewardship in Agribusiness Marta Gomez-Chiarri, Moderator Bruce Stewart-Brown, Senior Vice-President of Food Safety, Quality, and Live Operations, Perdue Foods Bill Keleher, President and CEO, Kennebec River Biosciences Craig Wilson, Vice President, GMM, Costco Wholesale Heather Fowler, Director of Producer and Public Health, National Pork Board 2:30 Adjourn PREPUBLICATION COPY: UNCORRECTED PROOFS

APPENDIX C C-9 JANUARY 8, 2020 OPEN FULL SCHEDULE IN EASTERN TIME 11:00-11:05 Welcome Guy Palmer, Committee Chair 11:05-11:35 Anthropology of Antimicrobial Resistance Clare Chandler, Professor in Medical Anthropology and Director, London School of Hygiene & Tropical Medicine 11:35-12:05 The Global Burden of Antimicrobial Resistance Chris Murray, Director, Institute for Health Metrics and Evaluation; Chair and Professor, Health Metrics Sciences, University of Washington 12:05 Open Session Adjourn CLOSED SESSION FULL SCHEDULE IN EASTERN TIME 12:05-12:20 Break 12:20-1:20 Debrief Guy Palmer, Committee Chair 1:20-2:00 Next Steps Guy Palmer, Committee Chair 2:00 Adjourn MARCH 16, 2021 OPEN SESSION 11:00-11:05 Welcome Guy Palmer, Committee Chair 11:05-11:35 GARDP and Antimicrobial Development Manica Balasegaram, Executive Director, Global Antibiotic R&D Partnership Jennifer Schneider, Senior Advisor External Affairs, Global Antibiotic R&D Partnership 11:35-12:05 Inpatient Reimbursement and the Antimicrobial Market Anand Shah, former Deputy Commissioner for Medical and Scientific Affairs, FDA 12:05 Adjourn Open Session PREPUBLICATION COPY: UNCORRECTED PROOFS

C-10 COMBATING AMR AND PROTECTING THE MIRACLE OF MODERN MEDICINE MARCH 16, 2021 CLOSED SESSION 12:15-12:30 Overview Draft Recommendations, Guidance on Writing Recommendations 12:30-3:00 Discussion of Draft Recommendations and Conclusions in Stewardship and Prevention 3:00 Adjourn MARCH 17, 2021 CLOSED SESSION 11:00-12:00 Discussion of Draft Recommendations and Conclusions on Push and Pull Incentives 12:00-12:15 Break 12:15-2:45 Discussion of Draft Recommendations and Conclusions on Diagnostics and Related Questions 2:45 Adjourn MARCH 18, 2021 CLOSED SESSION 11:00-12:00 Discussion of Draft Recommendations and Conclusions on International Action 12:00-12:15 Break 12:15-2:00 Discussion Draft Recommendations and Conclusions on Health and Economic Burden 2:00 Adjourn MARCH 19, 2021 OPEN SESSION 11:00-11:05 Welcome Guy Palmer, Committee Chair 11:05-11:45 Direct, Predictive Application of Sequencing and Informatics Gautam Dantas, Professor, Washington University School of Medicine 11:45 Adjourn Open Session PREPUBLICATION COPY: UNCORRECTED PROOFS

APPENDIX C C-11 MARCH 19, 2021 CLOSED SESSION 12:00-1:00 Discussion of Draft Recommendations and Conclusions on Surveillance 1:00 Adjourn MAY 11, 2021 CLOSED SESSION 11:00-2:00 Deliberation on Report Recommendations 2:00 Adjourn MAY 12, 2021 CLOSED SESSION 11:00-12:15 Deliberation on Report Recommendations 12:15-12:30 Break MAY 12, 2021 OPEN SESSION 12:30-1:30 Agencies’ Progress on National Action Plan, Mixed Methods Analysis Kris Moore, Medical Director, Center for Infectious Disease Research and Policy, University of Minnesota 1:30 End Open Session MAY 12, 2021 CLOSED SESSION 1:30 Debrief on Presentation 2:00 Adjourn MAY 13, 2021 CLOSED SESSION 11:00-2:00 Deliberation on Report Recommendations 2:00 Adjourn PREPUBLICATION COPY: UNCORRECTED PROOFS

C-12 COMBATING AMR AND PROTECTING THE MIRACLE OF MODERN MEDICINE MAY 14, 2021 CLOSED SESSION 11:00-2:00 Deliberation on Report Recommendations 2:00 Adjourn PREPUBLICATION COPY: UNCORRECTED PROOFS

Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine Get This Book
×
Buy Paperback | $45.00
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Antimicrobial resistance is a health problem that threatens to undermine almost a century of medical progress. Moreover, it is a global problem that requires action both in the United States and internationally.

Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine discusses ways to improve detection of resistant infections in the United States and abroad, including monitoring environmental reservoirs of resistance. This report sets out a strategy for improving stewardship and preventing infections in humans and animals. The report also discusses the strength of the pipeline for new antimicrobial medicines and steps that could be taken to bring a range of preventive and therapeutic products for humans and animals to the market.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!